-
公开(公告)号：US12128087B2
公开(公告)日：2024-10-29
申请号：US17369830
申请日：2021-07-07
Applicant: YALE UNIVERSITY
Inventor： Demetrios Braddock , Ronald Albright
IPC: A61K38/17 , A01K67/0271 , A61K38/02 , A61K38/04 , A61K38/46 , A61K48/00 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C12N9/96 , C12N15/52 , C12N15/62 , C12N15/85 , C12Q1/6883
CPC classification number: A61K38/1741 , A01K67/0271 , A61K38/02 , A61K38/04 , A61K38/46 , A61K38/465 , A61K48/0058 , A61P9/10 , A61P13/12 , C07K7/06 , C07K14/745 , C12N9/96 , C12N15/52 , C12N15/625 , C12N15/85 , C12Q1/6883 , C12Y301/04001 , C12Y306/01009 , A01K2207/15 , A01K2207/20 , A01K2227/105 , A01K2267/0387 , C07K2319/01 , C07K2319/30 , C07K2319/31 , C07K2319/33 , C07K2319/70 , C12N2840/007
Abstract: The present invention includes compositions and methods for treating diseases or disorders associated with pathological calcification or pathological ossification. In certain embodiments, the diseases or disorders are selected from the group consisting of Generalized Arterial Calcification of Infancy (GACI), Idiopathic Infantile Arterial Calcification (IIAC), Ossification of the Posterior Longitudinal Ligament (OPLL), hypophosphatemic rickets, osteoarthritis, calcification of atherosclerotic plaques, PXE, hereditary and non-hereditary forms of osteoarthritis, ankylosing spondylitis, hardening of the arteries occurring with aging, calciphylaxis resulting from end stage renal disease and progeria.
-
公开(公告)号：US20240307366A1
公开(公告)日：2024-09-19
申请号：US18581245
申请日：2024-02-19
Applicant: Zevra Denmark A/S
Inventor： Thomas Kirkegaard JENSEN , Marja H. JAATTELA
IPC: A61K31/4545 , A61K31/445 , A61K31/56 , A61K33/30 , A61K38/16 , A61K38/17 , A61K38/43 , A61K38/46 , A61K38/47 , A61K45/06
CPC classification number: A61K31/4545 , A61K31/445 , A61K31/56 , A61K33/30 , A61K38/16 , A61K38/17 , A61K38/1709 , A61K38/43 , A61K38/46 , A61K38/47 , A61K45/06 , C12Y306/01003
Abstract: Lysosomal membrane permeabilization is an evolutionarily conserved hallmark of stress-induced cell death. Here the inventors show that the major stress-inducible heat shock protein 70 (Hsp70) enhances cell survival by stabilizing lysosomes through a pH-dependent high affinity binding to an endo-lysosomal anionic phospholipid bis(monoacylglycero)phosphate (BMP; also referred to as lysobisphosphatidic acid). The positively charged ATPase domain of Hsp70 is responsible for the binding but the substrate-binding domain is also required for effective stabilization of lysosomes. Importantly, the cytoprotective effect can be obtained by endocytic delivery of recombinant Hsp70 and specifically reverted by extra cellular administration of BMP antibodies or Hsp70 inhibitors. Thus, this protein-lipid interaction opens exciting possibilities for the development of cytoprotective and cytotoxic lysosome-specific therapies for the treatment of degenerative diseases and cancer, respectively.
-
公开(公告)号：US20240238386A1
公开(公告)日：2024-07-18
申请号：US18560230
申请日：2022-05-10
Applicant: Marshall University Research Corporation
Inventor： Joseph I. Shapiro , Jiang Liu
Abstract: Methods for treating anemia are provided and include the steps of identifying a subject as having anemia characterized by a reduced number of red blood cells and then administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to the subject. Methods for increasing red blood cell half-life are also provided in which the polypeptide antagonist of a Na/K ATPase/Src receptor complex is either administered to a subject in need thereof or is made to contact a red blood cell.
-
公开(公告)号：US20240238385A1
公开(公告)日：2024-07-18
申请号：US18559936
申请日：2022-05-13
Applicant: Universidade do Algarve
Inventor： Clévio David RODRIGUES NÓBREGA , Rebekah COVACO KOPPENOL , Adriana Isabel DO VALE MARCELO , André Filipe VIEIRA DA CONCEIÇÃO
CPC classification number: A61K38/46 , A61K48/0033 , A61K48/005
Abstract: The present disclosure relates to an isolated or artificial nucleotide sequence encoding the GTPase-activating protein-binding protein 1 (G3BP1), for use in medicine, preferably in the treatment of polyglutamine diseases. Furthermore, the present invention is also related to a vector comprising such sequence, a host cell comprising such vector, a protein G3BP1, or a composition thereof, for use for use in medicine, preferably in the treatment of polyglutamine diseases.
-
5.发明公开公开(公告)号：US20240150736A1
公开(公告)日：2024-05-09
申请号：US18411592
申请日：2024-01-12
Applicant: DENALI THERAPEUTICS INC.
Inventor： Tina GIESE , Gunasekaran KANNAN , Mihalis S. KARIOLIS , Cathal S. MAHON
CPC classification number: C12N9/14 , A61K38/46 , A61P3/00 , C12Y310/01001 , C07K2319/30
Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
-
Patent Agency Ranking
公开(公告)号：US11944668B2
公开(公告)日：2024-04-02
申请号：US16327393
申请日：2017-08-23
Applicant: PEPSIS LIMITED
Inventor： John Hunter , Rosemary Waring
Abstract: The invention concerns the improvement of metabolic and digestive health of humans by providing diagnostic methods for enterometabolic disorders such as IBS and IBD and/or the treatment of IBS and IBD by compositions comprising enzyme rich malt extract (ERME).
-
公开(公告)号：US11938125B2
公开(公告)日：2024-03-26
申请号：US17688189
申请日：2022-03-07
Applicant: Zevra Denmark A/S
Inventor： Thomas Kirkegaard Jensen , Marja H. Jaattela
IPC: A61K31/4545 , A61K31/445 , A61K31/56 , A61K33/30 , A61K38/16 , A61K38/17 , A61K38/43 , A61K38/46 , A61K38/47 , A61K45/06
CPC classification number: A61K31/4545 , A61K31/445 , A61K31/56 , A61K33/30 , A61K38/16 , A61K38/17 , A61K38/1709 , A61K38/43 , A61K38/46 , A61K38/47 , A61K45/06 , C12Y306/01003
Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.
-
公开(公告)号：US20240041992A1
公开(公告)日：2024-02-08
申请号：US18377890
申请日：2023-10-09
Applicant: NanoCell Ltd.
Inventor： Irit SAGI , Inna SOLOMONOV , Eldar ZEHORAI
CPC classification number: A61K38/4886 , A61K38/46 , A61P15/00 , A61B17/435 , A61D19/04 , A61K9/0034 , C12Y304/24 , C12Y304/24007
Abstract: The present invention relates to a method for increasing the embryo implantation rate in a mammalian uterus, by administering to the uterus of a mammal an effective amount of an extracellular matrix remodeling enzyme, as well as to a product comprising an extracellular remodeling enzyme.
-
公开(公告)号：US11884944B2
公开(公告)日：2024-01-30
申请号：US17855543
申请日：2022-06-30
Applicant: DENALI THERAPEUTICS INC.
Inventor： Tina Giese , Gunasekaran Kannan , Mihalis S. Kariolis , Cathal S. Mahon
CPC classification number: C12N9/14 , A61K38/46 , A61P3/00 , C12Y310/01001 , C07K2319/30
Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
-
公开(公告)号：US20230279372A1
公开(公告)日：2023-09-07
申请号：US18018981
申请日：2021-07-30
Applicant: Ohio State Innovation Foundation
Inventor： Kristin STANFORD , Daniel GALLEGO PEREZ , Mark ZIOLO
CPC classification number: C12N9/14 , A61K38/46 , C12Y303/02003 , A61P9/00
Abstract: The present disclosure relates to compositions for regulating lipokines and methods of use thereof.
-
-
-
-
-
-
-
-
-
Search Results
432
records
(took 0.024 seconds)
